ABSTRACT: With the emerging popularity of immune-modulatory therapies to treat human diseases there is a need to step back from hypotheses aimed at assessing a condition in a single-system context and instead take into account the disease pathology as a whole. In complex diseases, such as amyotrophic lateral sclerosis (ALS), the use of these therapies to treat patients has been largely unsuccessful and likely premature given our lack of understanding of how the immune system influences disease progression and initiation. In addition, we still have an incomplete understanding of the role of these responses in our model systems and how this may translate clinically to human patients. In this review we discuss preclinical evidence and clinical trial results for a selection of recently conducted studies in ALS. We provide evidence-based reasoning for the failure of these trials and offer suggestions to improve the design of future investigations.
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we evaluated evidence for late-stage activation of central immune responses, particularly microglial activation in response to degenerating motor neurons, yet we also questioned whether this has any true impact on disease pathogenesis given its appearance after cell death. It remains inconclusive whether monocytes and macrophages directly influence disease progression. The presence of T lymphocytes in the spinal cords of postmortem ALS patients and endstage ALS mice supports the role of an adaptive immune response at later disease stages, but earlier humoral immune responses remain largely unexplored. Finally, the multifunctional role of the human leukocyte antigen/major histocompatibility complex (HLA/MHC) in the central nervous system (CNS) adds complexity to predispositions for immune dysregulation in disease.
There is a burgeoning interest in the role of neuroinflammation and immunity in ALS. Eleven of the trials mentioned in Table S1 (refer to Supplementary Material available online) are from the past 3 years with 8 of these still ongoing or planned, emphasizing the growing number of these types of intervention. The body of this review focuses on those studies with the most comprehensive information that has been published so far in peer-reviewed journals, with an emphasis on including representative trials for various domains of the immune system. We believe a thorough understanding of previous failed therapies may inform future study design. Study design, power, and mechanistic rationale for each randomized clinical trial discussed herein is presented in Table S1 in the Supplementary Material. Complete study results are presented in Table S2 in the Supplementary Material.
INNATE IMMUNITY
We start by discussing trials in which therapies primarily modulated innate immunity, specifically monocyte-derived cell populations. The first 2 of these therapies were not primarily meant as immune modulators but each is also reported to have such effects.
Celecoxib. Celecoxib is a United States Food and Drug Administration (FDA)-approved cyclooxygenase-2 (COX2) inhibitor that blocks prostaglandin synthesis. Prostaglandins stimulate astrocytic glutamate release 2, 3 and, with glutamate excitotoxicity being a known pathological event in ALS, COX2 seems a logical therapeutic target. Prostaglandin E 2 (PGE 2 ) has been accepted as a biomarker for COX2 activity in tumorigenic tissue 4 ; however, COX2 and prostaglandin products are also crucial homeostatic regulators of acute and chronic immune and inflammatory responses, especially as it relates to macrophage polarization. 5 Preclinical Data. Animal. The majority of preclinical data supporting the use of COX2 inhibitors in ALS have come from work in the mutant superoxide dismutase 1 (mSOD1 G93A ) mouse model. 6 Protein signatures for COX2 and PGE 2 , but not COX1, first accumulate in ventral spinal cord starting at p90 and peak at end stage (see Fig. 1 in part I of this study 1 ); COX2 protein is localized mainly within ventral horn neurons surrounding reactive astrocytes. 7 If associated with restraining astrocyte activation, which can be toxic to motor neurons, COX2 inhibition may be protective.
Multiple studies have tested the potential significance of COX2 inhibition on disease progression in the SOD1 mouse model. [8] [9] [10] [11] Two studies had mixed results of unknown relevance because of powering issues; both showed spinal cord PGE 2 inhibition, indicating that the agent was effective, but the lack of significant effect on disease onset or survival suggested no influence on pathology. 8, 9 However, in the only of these studies appropriately powered according to guidelines for testing treatment efficacy in the SOD1 mouse, 12 oral administration of celecoxib beginning at p28 (see Fig. 1 in part I of this study 1 ) significantly reduced spinal cord levels of PGE 2 and increased survival by 28 days.
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Patient. Postmortem ALS spinal cord tissue from 5 patients showed elevated PGE 2 compared with neurological controls without spinal cord pathology. 7 Another study in 9 ALS patients showed elevated PGE 2 in the cerebrospinal fluid (CSF), 12 but it is apparent from the individual data that there was a wide range of values, with nearly half of the ALS subjects falling into the control range. Unlike the mouse studies, the study found no correlation between PGE 2 levels and disease duration.
Clinical Trial and Interpretations. A 1-year-long, double-blind, placebo-controlled, randomized, clinical trial (RCT) of celecoxib 13 was conducted in which celecoxib was administered at twice the recommended dose for rheumatoid arthritis (RA) and compliance was assessed by measuring drug serum levels. The clinical trial followed PGE 2 as a presumptive biomarker of COX2 activity and inhibition. A beneficial effect was not detected. The authors indicated that further studies of celecoxib at this dose are unwarranted and elaborate a comprehensive discussion of reasons for the trial's failure, some of which are briefly covered here.
COX2 inhibitors suppress anti-inflammatory macrophage signaling, driving a pro-inflammatory environment theoretically capable of accelerating neuromuscular junction (NMJ) denervation by attracting pro-inflammatory macrophages to muscle. 14, 15 Potential detrimental effects exist in the CNS as well: COX2 is reported to have a key role in resolution of neuroinflammation by causing the death of overactive microglia and, in animal models, celecoxib prevents this activity. 16 This reveals the possibility that any CNS-positive effects from celecoxib's anti-excitotoxicity mechanism could be masked by disrupted homeostatic control of hyperactive microglia.
In preclinical animal trials, treatment was started relatively early in the disease process. However, some patients in the clinical trial began treatment up to 5 years after symptom onset. As in many ALS human trials, variability in this patient population confounds detection of potential therapeutic effects in a specific subset. As discussed in part I of this review, 1 it remains unclear whether immune processes are involved in ALS pathology. As such, it is critical that future patients selected inflammatory-modulating trials be screened for active inflammation.
The study attempted to monitor a biomarker of drug efficacy, namely PGE 2 protein in the CSF. Human studies have supported use of serum PGE 2 as a biomarker of COX2-inhibitor-produced analgesia, and tissue levels of PGE 2 respond to COX2 inhibitors in the SOD1 mouse 17 ; however, further issues remain: in the SOD1 mouse, COX1, not COX2, is the primary source of PGE 2 . It has even been postulated that neurodegeneration in this model occurs independently of PGE 2 . 18 In the clinical trial, overall CSF PGE 2 levels did not decline with treatment and, even in a post-hoc subanalysis of treated patients who did show decreased PGE 2 levels compared with those who did not, there was no difference in outcome measures. These findings could be due to a variety of issues (refer to Maihofner et al.
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), such as the small number of patients willing to do a second lumbar puncture (LP), that CSF levels of PGE 2 do not necessarily reflect COX2 activity in the CNS (as preclinical work looked mainly at spinal cord tissue itself ), or that the levels were not elevated at baseline.
It appears that COX2 activity is necessary to maintain blood-brain barrier (BBB) integrity during innate immune activation. 19 Inhibition of COX2 may therefore have an unintentional detrimental effect of increasing BBB permeability. The BBB permeability and its significance in human ALS has yet to be reliably characterized, with existing observations limited and inconclusive. [20] [21] [22] [23] Finally, given the preclinical evidence of when (end stage in mouse and postmortem in human-both after substantial denervation) and where (primarily neuronal) COX2 is observed, it is possible that COX2 does not have a role in disease onset or progression but rather simply reflects a reaction to the neuronal death and surrounding gliosis, itself triggered by degeneration. Although there was extension of survival in the mouse model, no investigation into inhibition or delay of specific pathological events (e.g., NMJ denervation, glial activation, or motor neuron survival) were reported.
Minocycline. Minocycline is an FDA-approved, broadspectrum tetracycline antibiotic typically prescribed for skin infections. [24] [25] [26] Oral minocycline is known to cross the BBB to reach active CSF concentrations. 25 Preclinical Data. Animal. Multiple separate studies using 2 different ALS mouse models demonstrated that starting treatment before significant functional motor deficits can prolong survival. [26] [27] [28] [29] However, none of these studies were powered to detect efficacy, as they were likely conducted before the published guidelines. 12 Although inhibition of cell death can extend survival, it is not sufficient to prevent earlier pathology, including NMJ denervation and glial activation. 30, 31 Potential effects of minocycline include not only promoting neuronal survival but also inhibiting inflammatory activation of microglia. 32 However, it is not clear whether these effects are related. Further complicating interpretations, another report showed that administration of minocycline actually enhanced activation of astrocytes and microglia. 33 Minocycline is also reported to have polarizing effects on monocyte-lineage cells, 34, 35 and in peripheral nerves it may inhibit macrophage response to axonal injury. 36 It is not known whether this is a protective or detrimental effect in ALS.
Clinical Trial and Interpretations. Two safety human trials of minocycline in ALS were completed, with a range of doses, but they were not powered to look at functional decline. 37, 38 A multicenter, phase III RCT of minocycline in ALS was conducted over a 9-month period. 39 The study was terminated when it was determined that minocycline had a harmful effect on patients. The rate of decline based on the revised ALS Functional Rating Scale (ALSFRS-R) was 25% faster in the treated group, mainly attributable to losses in gross motor function. Because the preclinical human studies were not powered for functional decline, they could have missed the deterioration reported in the phase III trial treatment group, as post-hoc analyses of that trial indicated that the worsened outcomes were not caused by adverse events.
The reported pro-survival and anti-inflammatory effects of minocycline were the basis for the rationale of this trial. However, preclinical work in the mouse models was underpowered. As discussed earlier, the mechanisms of action of this agent on neurons, microglia, astrocytes, and peripheral macrophages are not clear. Furthermore, potential beneficial or detrimental roles of these cells in disease pathology may not be linear, with beneficial effects countered by toxic effects.
The BBB may also play a role in the negative results of this trial. A recent review on BBB-driven pharmacoresistance in ALS therapies highlights how treatments that act as substrates for multidrug efflux transporters (e.g., P-glycoprotein [P-gp]), may have decreased therapeutic benefit in diseases where P-gp expression is increased at the BBB, such as ALS. 40 Minocycline is a substrate for P-gp, highlighting the possibility that it was effectively pumped out of the CNS in all or a subset of patients with higher expression of P-gp. This is especially relevant as the proposed therapeutic mechanism of action of minocycline requires CNS penetration and the peripheral effect of the drug could have been to limit a potentially helpful macrophage response to peripheral nerve injury. 36 Glatiramer Acetate. Two separate trials have been conducted to evaluate the effect of glatiramer acetate (GA) on ALS. GA treats multiple sclerosis of the relapsing-remitting type (RRMS) to reduce frequency of flare-ups. The majority of information on the mechanism of action comes from multiple sclerosis (MS)-centric studies.
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Pre-clinical Data. Preclinical work in ALS animal models showed inconsistent success with GA, with results varying by animal strain, background, gender, and co-administration of Freund's adjuvant. [44] [45] [46] The vast majority of experimental evidence for the actions of GA has come from human MS patients and animal models (experimental autoimmune encephalitis). However, the assumption of equivalent responses to GA in human MS and ALS patients may be problematic. Studies with cultured T lymphocytes from treated animals show inverse T-helper 1 (Th1) and Th2 cytokine responses: with treatment, these cytokines (interferon-gamma [IFN-γ] and interleukin-4 [IL-4]) were decreased in ALS, yet increased in MS, indicating disease-specific effects of GA on T-cell differentiation. 44, 47 Clinical Trials and Interpretations. A phase 2 RCT compared the effect of GA-exposed T-cell proliferation between ALS patients treated daily and biweekly and untreated controls. The authors theorized that less frequent dosing regimens would favor a predominantly protective Th2 response. 47 After 6 months, the daily injection group was more similar to controls, whereas there was an inverse pattern in the biweekly group. 48 The authors pointed out that this could have been because the less frequent dosing group had induced more T-regulaory (Treg) cells. However, although the study followed clinical outcomes as a safety measure, information was not reported on the functional decline of patients.
The second study was a 1-year-long, double-blind, multicenter RCT with significant power to detect clinical progression. 49 Although the results were negative for all outcomes followed, neutralizing antibodies and pharmacodynamic markers to predict the activity of GAs proposed immunomodulatory action were not monitored, and thus it cannot be assumed that the lack of functional improvement reflected a failed physiological mechanism.
The authors pointed out that lack of a clear marker for either transport through the BBB of immunocompetent cells or presence of CNS action is a major hurdle in assessing effectiveness as penetration of GA-responsive T cells through the BBB is a key factor in the biological activity of GA treatment in MS. In ALS, involvement of T cells in disease onset and progression is unclear (see part I of this review 1 ). Further, there may be differences between BBB disruption in these 2 diseases and it is possible that these GA-responsive T cells were unable to reach the CNS in ALS patients.
It is also noteworthy that many drugs targeting the immune system have a modulatory effect at lower doses but are purely immunosuppressive at higher doses. The dose used was twice the commonly studied and recommended dose of GA for MS. Predominantly immunosuppressive treatments, such as total lymphoid irradiation or high-dose pulse cyclophosphamide, were reported to be ineffective in slowing the progression of ALS. 50, 51 NP001. NP001 is a pH-adjusted, stabilized form of a sodium chlorite drug previously used for postradiation syndrome in AIDS. 52 Preclinical Data. A non-peer-reviewed study in SOD1 mice, described in a press release, 53 is the only apparent preclinical animal model evidence.
Clinical Trials and Interpretations. Because there was an effect of NP001 on extending the lifespan of the SOD1 mouse when administered before overt functional impairment (model/survival specifics unknown), 53 a phase 1, placebo-controlled, single ascending-dose safety and tolerability trial was carried out in 32 patients (0.2, 0.8, 1.6, and 3.2 mg/kg intravenously). 54 Before initiating the phase 1 study, researchers isolated and characterized monocytes from the blood of ALS patients for expression of CD16 and HLA-DR, to define potential biomarkers that changed with NP001 treatment. 54 55 and may represent the most mature of the circulating monocyte population. Many studies, both in vivo and in vitro, have shown CD16 (FcγIII receptor) as an antigen associated with expression patterns characteristic of tissue macrophages. [56] [57] [58] The CD16 + CD14 + HLA-DR + peripheral blood mononuclear cells (PBMC) characteristically release little or no anti-inflammatory IL-10 but are a major source of proinflammatory tumor necrosis factor-alpha (TNF-α) in response to lipopolysaccharide (LPS) and show higher potency toward antigen presentation. 55, 58 This particular subset has been observed as altered in autoimmune disorders; it is expanded and preferentially activated in MS, but reduced and dysfunctional in systemic lupus erythematosus. 59, 60 Monocyte markers are logical investigative biomarkers for disease activity given the evidence for macrophage activation in ALS, as described in part I of this review, 1 and that, in the animal model, cells expressing the mouse equivalent of CD16 accumulate within the spinal cord as disease progresses. These markers specifically relate to alterations of blood monocyte populations that occur with disease progression. Two separate studies using peripheral blood from a total of 80 sporadic ALS patients exhibited elevated CD14 + CD16 + monocytes, characterized by high HLA-DR and low C-C chemokine receptor type 2 (CCR2) compared with healthy and neurological disease controls (Alzheimer's disease + agerelated macular degeneration). 61, 62 CCR2 is expressed on the surface of monocytes and mediates their chemotaxis in response to monocyte chemoattractant protein-1 (MCP-1). 63 Increased HLA-DR could predispose cells to be self-reactive, whereas the low responsiveness to chemotaxis through CCR2 may inhibit beneficial responses, such as clearing cellular debris.
Miller and colleagues found that, in agreement with the previous data, at baseline, blood monocytes from ALS study subjects showed increased monocyte activation (CD14 , CD16 levels were positively related to the estimated rate of ALS progression. 54 At 24 hours after dosing, monocyte HLA-DR expression had decreased in all patients who had shown an elevated baseline; the magnitude of reduction correlated positively only with the level of baseline elevation. In contrast, there was an observed dosedependent change in monocyte CD16 expression not correlated with baseline expression.
Because there was no dose dependence in HLA-DR expression reduction, the authors speculated that HLA-DR monocyte expression indicates systemic inflammation, and therefore the minimally effective dose (0.8 mg/kg) that reduced monocyte HLA-DR is reflective of a global anti-inflammatory response. However, NP001 appeared to have an immune-modulatory effect at higher doses (1.6 and 3.2 mg/kg), effectively reducing CD16 + CD14 + HLA-DR + monocyte activation, potentially affecting monocyte migration from blood to tissue. Again, this illustrates the importance of considering dose when attempting to suppress or modulate immune responses.
The follow-up, phase 2, double-blind, multicenter RCT of NP001 utilized the higher, hypothetically immune-modulatory, doses for a 6-month treatment period. 64 The study evaluated plasma levels of many inflammatory molecules (Table S1 ), but did not attempt to replicate the previous study's findings for peripheral monocyte HLA-DR or CD16 with prolonged administration. There were non-significant effects of a trend toward a slower decline, but the magnitude of this decline (<20%) was below the study's power, potentially indicating a need for future studies powered to detect a smaller effect.
The post-hoc analysis on subjects from the study suggested "responders" to this therapy-those patients whose ALSFRS-R did not change from baseline during the treatment period-of which there were twice as many in the treatment group (25%) than in either control group (11%). At baseline, the responders had elevated IL-18, a pro-inflammatory factor produced by M1 macrophages, and were positive for LPS, a potent M1 phenotype inducer. Notably, over the study period, patients in the placebo group either became LPS + or showed increasing levels of LPS, regardless of clinically measurable disease progression. These results suggest that LPS accumulation in ALS patients may be part of the disease progression and a trigger for further inflammatory responses that may exacerbate disease progression.
The presence of circulating LPS in ALS, more than in any other neurological disease, has been described in multiple studies, but it remains unclear whether this represents part of the disease pathogenesis or is related to underlying infectious processes occurring in this often fragile population. 65, 66 LPS may be produced by the aerobic or facultatively anaerobic gramnegative bacteria that inhabit the mucosal surfaces of the respiratory tract and gut, 67 and, in the case of a "leaky gut" (an impaired mucosal barrier), this LPS will leak into the systemic circulation. 68 The SOD1 mouse has been reported to have an impaired gut mucosal barrier and this phenomenon has been observed in humans in other neurodegenerative diseases, although this issue is still strongly debated. 69, 70 Observations regarding circulating LPS in ALS patients merit further exploration, especially in determining whether macrophage polarization is a direct result of these circulating levels or if they are reflective of impaired mucosal barriers or another separate pathogenic process, as suggested in recent work with IL-6 and dendritic cells. 71 The authors mentioned what they believe may have been a dose-response effect: twice as many patients on the high dose (25%) did not progress as compared with those on the low dose (11%) or the historical control group (HCG, 10%). Randomization accounted for baseline ALSFRS-R score but another potential explanation for this finding is that the high-dose group had the smallest percentage of subjects who completed 6 cycles (35 of 45 subjects). Those who did not complete the study due to death or drop-out were likely those with more severe progression. Within the high-dose group, the "responders" had elevated baseline IL-18, IL-6, IFN-γ, and C-reactive protein (CRP) and were positive for LPS. After 6 months of treatment, 70% of those in this group (6 subjects) showed decreased LPS and 80% had decreased IL-18. However, there was no change in the other pro-inflammatory biomarkers, including CRP, which was later shown to correlate with severity of functional impairment in this same population, 72 leaving the significance of these decreases uncertain.
Importantly, although patients were randomized based on their baseline ALSFRS-R score, baseline disease progression (slope of ALSFRS, ΔFRS, etc.) was not accounted for. This leaves open the possibility that the responder group was actually comprised of those with a slowly progressing phenotype or that the responder status was associated with the physiological state of an "ALS plateau" rather than any effect due to treatment. Even with randomization, only a longitudinal observational study would be able to answer the question of an immunological signature for an ALS plateau.
ADAPTIVE IMMUNITY
In this section we discuss studies that attempted to modulate adaptive immune response, chiefly that of T cells. Total lymphoid irradiation (TLI), which selectively targets lymphoid tissue, is an attempt at abolishing circulating lymphocytes for a long period of time. These cells have been observed in the spinal cord of ALS patients at autopsy and are known to induce proinflammatory microglial phenotype(s). 73 A prospective, double-blind, RCT assessed treatment of ALS patients with TLI or sham radiation, with follow-up for 2 years. 50 There was a maintained reduction in circulating CD3 + and CD4 + Th cells. Interestingly, in the TLI-treated patients, the number of cytotoxic CD8 + T cells (Tc) increased significantly, and the number of B cells increased to 3 times baseline levels after treatment. Nonetheless, there was no difference in functional decline or survival of irradiated patients. Posthoc analysis combining the leukocyte subset analyses and immunity challenges (see Table S1 online) further showed that more effective immunosuppression by these measures did not correlate with a more favorable disease course. Together, these results suggest that circulating lymphocytes do not play a role in mediating disease progression.
Fingolimod. Fingolimod phosphate was the first approved oral therapy for MS. It is proposed to work by 2 mechanisms. Fingolimod reduces effector lymphocytes exiting the secondary lymph organs, limiting migration of pathogenic T cells into the CNS while also increasing the proportion of circulating, protective, Treg cells-thus, it causes population redistribution rather than complete depletion of lymphocytes. 74 Also, after systemic administration, this lipophilic drug readily enters the CNS where endogenous sphingosine kinases generate fingolimod's active form, which promotes the neuroprotective effects of microglia, downregulating proinflammatory cytokine production, just as it downregulates peripheral pro-inflammatory cytokines from macrophages. 75, 76 Theoretically, downregulation of these pro-inflammatory cytokines prevents central migration of peripheral monocyte-derived cells.
Preclinical Data. Animal. Administration of fingolimod into the late-stage SOD1 mouse showed prolonged survival by 15 days, but it did not improve performance on the rotorod or prevent weight loss. 77 These results must be considered with caution because the study was not powered for efficacy. 12 Clinical Trials and Interpretations. Recently, results were published of a phase IIA RCT on treating ALS patients for 1 month with the dose of fingolimod approved by the FDA for MS. 78 Although not powered for efficacy, the study sought to determine whether circulating lymphocytes and their subsets could serve as a pharmacodynamic marker of target engagement. As expected, total lymphocyte count decreased and the decline in CD4 + :CD8 + ratio suggested that CD4 + cells were more effectively sequestered. The authors noted that, given the rapid and robust decrease in the circulating lymphocytes, the dose may be too high for immune modulation, instead completely suppressing the responses. Indeed, the FDA NDA review of fingolimod determined that the 0.5-mg/day dose was higher than the observed half-minimal inhibitory concentration (IC 50 = 0.345). 79 The preferential sequestration of CD4 + T cells may prove especially beneficial in ALS as, unlike in MS, the T-cell infiltrate observed in ALS postmortem human spinal cord is primarily CD4 + . 80 However, because Treg cells are part of the CD4 + subset, it may be that these infiltrates are representative of an attempted protective response rather than a detrimental pathogenic mechanism. Indeed, with treatment, PBMC expression of Fox3p was reduced. Given that a lower level of Foxp3 correlates with a more rapid decline and patients with more Treg (CD4 + /CD17 + ) cells have slower progression, 81 preferential sequestration of CD4 + may be detrimental. The authors agreed that absolute reduction in Foxp3 in the absence of other immune-related gene changes would be a cause for caution and that quantification of the specific Treg subset could be included in future studies. A dose-response study may be able to determine the ideal dose for immune modulation, or the drug may have to be titrated on an individual basis to Fox3p or CD4 + / CD17 + (Treg) levels. Future larger studies could also consider monitoring circulating lymphocyte subsets within the CNS.
CYTOKINE RESPONSES
As messengers that coordinate the innate and adaptive responses, pro-inflammatory cytokines are well suited to modulate inflammation and thus have been pursued as potential drug targets for treatment of ALS. As mentioned in part I of this review, 1 interactions between T cells and peripheral macrophages and the ability of these macrophages to bias the T-cell response could be a more effective target in ALS than attempting to modulate the T-cell response itself.
Anakinra. IL-1β is an important mediator of inflammation, but is also involved in cell proliferation, differentiation, and apoptosis. Monocyte-lineage cells can produce a pro-protein that is cleaved by caspase-1 into active IL-1β in response to various danger signals, including non-microbial ones from the inflammasome. 82 Both mutant SOD1 and TDP-43 are reported to activate microglia through the inflammasome, upregulating IL-1β. 83, 84 Anakinra is a recombinant human IL-1R antagonist protein that limits the effects of IL-1β and is FDA-approved to treat RA.
Preclinical Data. Conflicting evidence exists regarding the role of IL-1β in ALS, as a response to or an augmentor of neurodegeneration, and preclinical studies of anakinra itself in the disease are very limited. 85, 86 Administration of anakinra to the SOD1 mouse resulted in only a 6-day increase in survival, and transgenic deficiency of IL-1β showed a 10-day increase. 83 Although the study was adequately powered for efficacy, results suggest only minimal improvement. The relative reduction in microgliosis and astrogliosis in the spinal cord of treated animals at the end stage suggest the agent did reach the CNS. Taken together, this and other trials suggest IL-1β has a limited role in disease progression in the mouse model. 87 Clinical Trials and Interpretations. For a human trial of anakinra in ALS, researchers chose to treat patients with dominant or exclusive lower motor neuron degeneration for 1 year with the hypothesis that inflammation at peripheral nerve fibers is more accessible to the drug. 88 There were no differences in clinical outcomes between treated patients and an HCG. The utility of HCGs to assess treatment efficacy in clinical trials depends greatly on the similarity between the current control arm and the historical data. 89 However, the study did not have a current control arm, leaving open the possibility that the HCG was not properly matched, especially given the discrepancies between gender in the treatment group and HCG (6% vs. 39% female, respectively). Regardless, the study was not powered for efficacy but instead evaluated the change in serum cytokines and inflammatory markers.
Unlike some previously discussed studies, here the chosen markers indicated modulation of the inflammatory response rather than overt immune suppression, consistent with the multifactorial effects of ILs. The 2 acute-phase reactants measured showed opposing results: fibrinogen was persistently decreased throughout the trial, whereas CRP levels rose with time. Mean levels of IL-6 and TNF-α had trended down by 24 weeks, but then increased, along with neutrophil number, for the remainder of the study. The authors suggested that this is suggestive of secondary ineffectiveness in the latter half of the study, potentially due to the antibodies generated by 94% of subjects against anakinra.
It remains unknown whether treatment with anakinra can be effective in ALS patients. Anakinra could cross the BBB and reach effective concentrations in mice 90 and humans with subarachnoid hemorrhage, 91 but CSF levels were not monitored in the study so it remains unclear whether the drug had any central effects. Because the animal study with an IL-1 receptor antagonist demonstrated reduced gliosis in the CNS of treated animals, 86 it may be worth examining the central effects of blocking IL-1β in humans with PBR-28 positron emission tomography scans. If CNS IL-1β and microglial activation contribute to disease progression, administration of CNS anakinra may be effective at delaying disease progression. Carefully controlled and monitored studies are necessary to further determine its potential therapeutic value.
Tocilizumab. IL-6 is a key regulator of inflammation and has been reported as elevated in the serum and CSF of ALS patients in a number of studies. [92] [93] [94] [95] IL-6 expression increases in pathological events that occur in all ALS patients, namely muscle atrophy and compromised respiratory function. [96] [97] [98] IL-6 regulates resting T cells by controlling proliferation and resistance to apoptosis. Tocilizumab is a humanized monoclonal antibody against the IL-6 receptor and is FDA approved for the treatment of RA.
Pre-RCT Data and Ongoing Clinical Trial. Two small human studies (≤10 subjects) demonstrated the potential utility of blocking IL-6 with the drug tocilizumab in a subset of responsive patients. 92, 99 As a result, the ongoing phase II RCT treating ALS patients with tocilizumab is the first ALS clinical trial using immune or inflammatory modulatory therapies that attempted to recruit a defined study population of "responders" based on preclinical evidence.
Interpretations. Although a well-defined inflammatory modulator, the ultimate effect of IL-6 is dependent on the receptor and cell type activated. In "classical" signaling, IL-6 activates limited cell types via the membrane-bound IL-6 receptor (mIL-6R). Through ectodomain shedding of the soluble receptor, sIL-6R, "trans-signaling" dramatically increases the number of IL-6 target cells. 100 Trans-signaling promotes a pro-inflammatory milieu of Th17 effector cells where CD4 + T cells are activated to produce Th2 cytokines while inducible, anti-inflammatory Treg responses are suppressed. [100] [101] [102] [103] [104] Indeed, IL-6 trans-signaling is considered the pathologically relevant IL-6 mechanism in disease. 105 Specific blockade of sIL-6R trans-signaling relieves multiple human inflammatory diseases in animal models and patients, with correlations between IL-6 levels and anti-inflammatory therapy responsiveness. [104] [105] [106] [107] [108] [109] The pathogenic importance of the IL-6 transsignaling mechanism poses problems for preclinical animal trials attempting to block IL-6. There are species-specific shedding mechanisms of IL-6R: mice and humans use ADAMS10, but only humans use ADAMS17, with this being the major protease responsible for generation of sIL-6R. 110 In fact, SOD1 mice treated with MR16-1 (the tocilizumab mouse analog) showed none of the patterns in serum cytokines seen in either group of human patients from the preclinical trials. 111 It is crucial to consider that the roles of IL-6 trans-signaling in neurodegenerative diseases may vary in different disease stages and may depend on the ratios of IL-6 to sIL-6R, as this is known to influence the classical and trans-signaling balance. 112 Investigators in the current trial are addressing this by determining these levels within study subjects (clinicaltrials.gov NCT02469896).
CONCLUSIONS
Trial-and-error clinical trials are costly in dollars, effort, and time, and disappointment is inherent in multiple failures, both for patients and providers. The results of the trials discussed here were also discouraging and at first glance may seem not to have greatly advanced our understanding for specific roles of inflammation or immunity in ALS. Yet, some newer studies appear to be hopeful in their preliminary results and, regardless, the clinical data and biological samples collected from these trials have proven invaluable by helping identify new disease targets, biomarkers, genes, trial designs, prediction models, cooccurring disease modifiers, and non-pharmacological interventions (e.g., the information that continues to be a result of the PROACT cohort).
Several reasons may explain the failure of these discussed and other inflammatory-modulating drugs to slow disease progression in ALS patients, not all of which have been mentioned here. First, and possibly most crucial, ALS is a highly heterogeneous disease. Preclinical testing has often been done in the SOD1 mouse model, which, although still by far the most highly pathologically characterized model of the disease, represents the genetic cause for <2% of all human ALS cases. 6 In humans, it is possible, even likely, that not all patients have an enhanced inflammatory component to their disease, such as that seen in the SOD1 mouse. Thorough characterization of other ALS mouse and cellular models with correlation to specific disease pathologies will also likely be a better predictor for treatment success than overall organism survival. This also highlights the importance of using appropriately matched controls in human trials. The use of historical controls as an effective placebo in ALS clinical trials remains controversial. [113] [114] [115] [116] With regard to the heterogeneity of the disease, it would be advantageous to replicate results in multiple models before treatments are moved into human populations. For example, induced pluriponent stem cell motor neuron cell cultures will be useful for high-throughput drug screening and should be used as a complement to animal models, where the specific disease pathology can be examined in multiple tissues. This could also help limit undue influence by one positive study with results impossible to duplicate, which is often caused by the issue of biased publication for these positive studies. Cohort enrichment studies, such as those of the combined immunosuppressive regimen's "Group A" and tocilizumab (see Table S1 online), can also increase cohort biological homogeneity to those subjects most likely to respond positively to the specific treatment.
Second, we do not yet know the dynamics and nature of the interaction between the immune system and motor neuron death. Therefore, we do not know whether administration of immunomodulatory therapies after disease onset is too late, or even at a time when immune activation has a protective function. For example, if microglial activation is beneficial, as these activated cells remove dying neurons and support neuronal regeneration, then we would not want to hinder them. Indeed, inhibiting microglial activation does not affect the early disease course, suggesting that they are not having a negative effect at that point in time. 117 Third, we have not characterized BBB permeability in ALS, which likely changes with time as it does in other chronic neurodegenerative and inflammatory diseases, so often we do not know how or if these drugs are penetrating the CNS, or, in some cases, if we even want them to do so. Studies that lack markers of biological activity at the target tissue and those that have not appropriately investigated ideal dosing contribute to the confusion of failed hypothetical mechanism vs. failed delivery.
The current trial of tocilizumab begins to address various weaknesses of previous trials. By using preclinical data to identify a potential subgroup of responders, investigators have increased the chance of finding a significant treatment effect in a small trial. Cytokine profiling in plasma and CSF permits a comparison of how the drug and its effect may or may not be penetrating the BBB. Similar to the use of CRP as an enrichment biomarker for the phase 2 study of NP001, 63 previously classifying how PBMC pro-inflammatory gene expression changes in this group allows for assessment of target engagement beyond traditional measures, such as cytokine profiling. Finally, inclusion of PBR28 PET scans to measure glial activation could increase significance of this smaller type of study as compared with the ALSFRS-R scores traditionally used to assess patient response to treatment. 118 In fact, the ibudilast study (see Table S1 online; NCT02714036) currently underway is the first to be powered by PBR-28 positron emission tomography results.
An issue that remains for studies where an ideal responder subgroup is identified from the general population is that the clinical features of responders (such as muscle weakness or site of onset) are not overtly different from those of non-responders. This makes it impossible for clinicians to identify patients who would most likely respond to a drug without secondary testing. We propose that future trials include a thorough, critical review of available animal and patient preclinical data, and, if this is not available, initiate studies to gather such information. These data can be used to determine characterization of patient inflammatory and immune profiles that will be essential to identify potential responders. Furthermore, baseline characterization of known targets of therapeutic agents must be determined and utilized. Adjustments by basic and clinical researchers to appropriately power and analyze their studies by published guidelines can eliminate variability. However, even with these issues addressed, not fully understanding the immune response to ALS predisposes clinical trials of immune and/or inflammatory modulators to failure. We must learn more about the cross-talk between disease pathology and immune system responses to accurately determine what aspects of the response to modify, when to do this, and in what patients it will ultimately prove effective.
